Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir
- PMID: 3015009
- PMCID: PMC284174
- DOI: 10.1128/AAC.29.5.894
Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir
Abstract
Cross-resistance data for a group of nine acyclovir-resistant variants of herpes simplex virus type 1 are reported. These mutants, which express either altered thymidine kinase (TK) or DNA polymerase, were all derived from the same wild-type (wt) strain after exposure to acyclovir in tissue culture. Furthermore, all variants have pathogenic properties similar to the wt parental strain as assessed using mouse model systems (G. Darby, H.J. Field, and S.A. Salisbury, Nature (London) 289:81-83, 1981; B.A. Larder and G. Darby, Virology 146:262-271, 1985). Two groups of antiherpes compounds were used: those requiring activation by TK and those whose action is independent of that enzyme. The TK substrate-specificity mutants were generally resistant to the TK-activated drugs but showed wt susceptibility to phosphonoacetic acid, 9-beta-D-arabinofuranosyladenine, and aphidicolin. The DNA polymerase mutants were relatively susceptible to most TK-activated drugs, although two were resistant to 5-(trifluoromethyl)-2'-deoxyuridine. The polymerase mutants showed a more complex pattern of susceptibility, however, to those compounds whose mode of action is independent of TK. In general, these variants showed similar responses to phosphonoacetic acid, phosphonoformate, and 9-beta-D-arabinofuranosyladenine, a particular variant being either resistant, susceptible, or hypertensive to all three. The response of each variant to aphidicolin, however, appeared to be the inverse of its response to the other three drugs. The cross-resistance patterns are discussed, and their implications for combined or successive therapies are considered.
Similar articles
-
Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities.Virology. 1985 Oct 30;146(2):262-71. doi: 10.1016/0042-6822(85)90009-1. Virology. 1985. PMID: 2996220
-
Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. Evidence for virus variants expressing normal DNA polymerase and altered thymidine kinase.J Biol Chem. 1983 Feb 10;258(3):2027-33. J Biol Chem. 1983. PMID: 6296119
-
The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs.J Infect Dis. 1981 Feb;143(2):281-5. doi: 10.1093/infdis/143.2.281. J Infect Dis. 1981. PMID: 6260876
-
Significance of resistance of herpes simplex virus to acyclovir.J Am Acad Dermatol. 1988 Jan;18(1 Pt 2):190-5. doi: 10.1016/s0190-9622(88)70026-2. J Am Acad Dermatol. 1988. PMID: 2828441 Review.
-
A perspective on resistance to acyclovir in herpes simplex virus.J Antimicrob Chemother. 1983 Sep;12 Suppl B:129-35. doi: 10.1093/jac/12.suppl_b.129. J Antimicrob Chemother. 1983. PMID: 6313592 Review.
Cited by
-
Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.Drugs. 1989 Mar;37(3):233-309. doi: 10.2165/00003495-198937030-00002. Drugs. 1989. PMID: 2653790 Review.
-
Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition.Proc Natl Acad Sci U S A. 1988 Sep;85(18):6672-6. doi: 10.1073/pnas.85.18.6672. Proc Natl Acad Sci U S A. 1988. PMID: 2842788 Free PMC article.
-
In vitro mutagenesis of the herpes simplex virus type 1 DNA polymerase gene results in altered drug sensitivity of the enzyme.J Virol. 1989 Nov;63(11):4913-8. doi: 10.1128/JVI.63.11.4913-4918.1989. J Virol. 1989. PMID: 2552170 Free PMC article.
-
Genetic characterization of the vaccinia virus DNA polymerase: identification of point mutations conferring altered drug sensitivities and reduced fidelity.J Virol. 1991 Feb;65(2):869-79. doi: 10.1128/JVI.65.2.869-879.1991. J Virol. 1991. PMID: 1898973 Free PMC article.
-
Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1.Antimicrob Agents Chemother. 2024 May 2;68(5):e0011024. doi: 10.1128/aac.00110-24. Epub 2024 Apr 15. Antimicrob Agents Chemother. 2024. PMID: 38619252 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources